Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL1366

AURANOFIN
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available

Basic Information

ChEMBL ID CHEMBL1366
Name AURANOFIN
Phase Approved
Structure Type NONE
Therapeutic ✓ Yes

Known Names

Auranofin Auranofina Auranofine NSC-321521 Ridaura SK&F 39162 SK&F-39162 SK-39162
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
8
Known Names
14
Indications
1
Mechanisms

Molecular Properties

678.5
MW (Da)

Drug Information

Molecule Type Small molecule
First Approval 1985
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Oral

Flags

Black Box Warning Natural Product
USAN Year 1976

Extended Properties

Molecular Formula C20H34AuO9PS
MW 678.49

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Unknown - -

Indications

Arthritis, Rheumatoid Rheumatic Diseases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Ovarian Neoplasms Pain Tuberculosis Adenocarcinoma of Lung Amebiasis Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Glioblastoma HIV Infections Small Cell Lung Carcinoma

ATC Classification

M01CB03
auranofin
Level 1: MUSCULO-SKELETAL SYSTEM
Level 2: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Drug Warnings

Black Box Warning
hematological toxicity
Country: United States
Black Box Warning
gastrointestinal toxicity
Country: United States
Black Box Warning
nephrotoxicity
Country: United States
Black Box Warning
dermatological toxicity
Country: United States

Data from ChEMBL 36 via Core Engine